Clinical trial
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast…
NCT00288249 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00288249 |
|---|---|
| Title | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer |
| Official title | Prospective, Multicenter, Randomized, Independent-group, Open-label Phase II Study to Investigate the Efficacy, Safety and Tolerability of 4 Regimen With 3 Doses of ZK 219477 (16 and 12 mg/m2 Body Surface Area as 3-hour Infusion or 22 mg/m2 Body Surface Area as 30-minute or 3-hour Infusion) in… |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Breast Cancer, Metastatic |
| Intervention type | Drug |
| Interventions | Sagopilone (BAY86-5302, ZK 219477) |
| Enrollment | 82 |
| Start date | Dec 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Feb 7, 2006 |
| Last update posted | Dec 2, 2014 |
| Countries | Austria, Belgium, Bulgaria, France, Germany, Italy, Poland, Slovenia, Spain, United Kingdom |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: